



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/539,031	
				Filing Date	June 13, 2005	
				First Named Inventor	Rajagopal Bakthavatchalam	
				Art Unit	1625	
				Examiner Name	N. Rahmani	
Attorney Docket Number	60425(72021)					
Sheet	1	of	2			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	2003/0236280	12/25/2003	Codd et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 03/055848 A2	07/10/2003	Bayer Aktiengesellschaft		
	BB	WO2004/028440 A2	04/08/2004	Bayer Healthcare AG		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	Johansen, M.E. et al., "TRPV1 Antagonists Elevate Cell Surface Populations of Receptor Protein and Exacerbate TRPV-1-Mediated Toxicities in Human Epithelial Cells," <i>Toxicological Sciences</i> 89(1), 278-286 (2006) (Advance Access publication August 24, 2005).			
	CB	Thomas, Karen C. et al., "Transient Receptor Potential Vanilloid 1 Agonists Cause Endoplasmic Reticulum Stress and Cell Death in Human Lung Cells," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 321(3), 830-838 (2007).			
	CC	Bolcskei, Kata et al., "Investigation of the Role of TRPV1 Receptors in acute and chronic nociceptive processes using gene-deficient mice," <i>Pain</i> 117, 368-376 (2005).			
	CD	Helyes, Zsuzsanna et al., "Role of transient receptor potential vanilloid 1 receptors in endotoxin-induced airway inflammation in the mouse," <i>Am J Physiol Lung Cell Mol. Physiol.</i> 292(5):L1173-81 (2007).			
	CE	Banvolgyi, Agnes et al., "Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model," <i>J Neuroimmunol.</i> 169, 86-96 (2005).			
	CF	Treviani et al., "Antitussive activity of iodo-resiniferatoxin in guinea pigs," <i>Thorax</i> 59:769-772 (2004).			
	CG	Garcia-Martinez et al., "Attenuation of thermal nociception and hyperalgesia by VR1 blockers," <i>PNAS</i> 99:2374-79 (2002).			
	CH	Honore et al., "A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats," <i>J. Pharmacol. Exp. Therap.</i> 314:410-421 (2005).			
	CI	Ghilardi et al., "Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain," <i>J. Neuroscience</i> 25(12):3126-31 (2005).			
Examiner Signature				Date Considered	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/539,031
				Filing Date	June 13, 2005
				First Named Inventor	Rajagopal Bakthavatchalam
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	2	of	2	Attorney Docket Number	60425(72021)

	CJ	Nagy et al., "The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology," European J. Pharmacol. 500:351-369 (2004).	
	CK	Szallasi et al., "Vanilloid Receptor TRPV1 Antagonists as the Next Generation of Painkillers. Are We Putting the Cart before the Horse?" J. Med. Chem. 47(11):2717-2723 (2004).	
	CL	Xiang, et al., "Effects of airway inflammation on cough response in the guinea pig," J. Applied Physiol., 85:1847-54 (1998).	
	CM	Sasaki et al., "Effect of NS-21, an Anticholinergic Drug with Calcium Antagonistic Activity, on Lower Urinary Tract Function in a Rat Model of Urinary Frequency," Int. J. Urol., 4:401-406 (1997).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--